Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | RHOA | P61586 | 7/20 | 0.44 |
| ▸ | RHOC | P08134 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | USP2 | O75604 | 5/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24513571 | 1.00 | SCN9A (0.49) | SCN9AHIF1ARHOARHOCTSHR | |
| SCHEMBL24548420 | 0.85 | PDK1 (0.48) | SCN9AHIF1ARHOARHOCTSHR | |
| SCHEMBL24548421 | 0.85 | PDK1 (0.48) | SCN9AHIF1ARHOARHOCTSHR | |
| SCHEMBL24513565 | 0.79 | SCN9A (0.40) | SCN9AHIF1ARHOARHOCTSHR | |
| SCHEMBL30691979 | 0.76 | HIF1A (0.58) | HIF1ATSHRCYP3A4USP2CYP2C19 | |
| SCHEMBL1534232 | 0.75 | RHOA (0.54) | RHOARHOCCYP3A4 | |
| SCHEMBL13725365 | 0.75 | PDK1 (0.47) | SCN9APDK1 | |
| SCHEMBL3984592 | 0.75 | PDK1 (0.47) | SCN9APDK1GLRA1 | |
| SCHEMBL10264841 | 0.72 | HSP90AA1 (0.65) | — | |
| SCHEMBL30691969 | 0.71 | HIF1A (0.50) | HIF1ATSHRCYP3A4USP2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| WO-2022125984-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125987-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | MAPT, GAP43, RNMT | SCN9A 2397/4885HIF1A 3944/4885RHOA 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.